Antibody–drug conjugate I-DXd shows meaningful response in patients with extensive-stage small cell lung cancer
The antibody–drug conjugate ifinatamab deruxtecan (I-DXd) has shown clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (ES-SCLC), according to an interim analysis of the Phase ...
5 hours ago
0
0